Show simple item record

dc.contributor.authorConstantinidou, Anastasiaen
dc.contributor.authorJones, Robin Lewisen
dc.contributor.authorScurr, Michelle R.en
dc.contributor.authorAl-Muderis, Omaren
dc.contributor.authorJudson, Ian Roberten
dc.creatorConstantinidou, Anastasiaen
dc.creatorJones, Robin Lewisen
dc.creatorScurr, Michelle R.en
dc.creatorAl-Muderis, Omaren
dc.creatorJudson, Ian Roberten
dc.date.accessioned2018-06-22T09:52:47Z
dc.date.available2018-06-22T09:52:47Z
dc.date.issued2011
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41508
dc.description.abstractBackground. Aggressive fibromatosis (AF) is a locally invasive proliferative disease. The mainstay of treatment is surgery. Chemotherapy may be considered in inoperable AF following failure of hormonal therapy and/or NSAIDs. Material and methods. We conducted a retrospective search of the prospectively maintained Royal Marsden Hospital Sarcoma Unit database to identify patients with AF treated with chemotherapy between 1987 and 2009. Results. Thirty-nine patients, thirty one females and eight males, received one or more lines of chemotherapy. The most frequently employed chemotherapy regimens were methotrexate/vinblastine [MTX/VBL] (18) and pegylated liposomal doxorubicin [PLD] (14). MTX/VBL was administered weekly or every two weeks at MTX 50 mg and VBL 10 mg. Treatment duration ranged from three weeks to one year with a median of 4.5 months. Partial response (PR) was observed in 11% of cases, disease stabilisation (SD) in 60% and progressive disease (PD) in 22%. Time to progression ranged from one month to sixteen years. The main toxicities reported were mucositis (4), peripheral neuropathy (3), vomiting (3), and neutropenia (3). PLD was administered at 40-50 mg/m2 every four weeks, for up to six cycles. PR was achieved in 33% and in the remainder the disease was stable with no progression during treatment. Three (25%) patients have so far progressed after treatment. Symptomatic benefit, especially pain relief, was reported in 86% (12/14) of cases. Main toxicities included palmar plantar erythema (5) and mucositis (4). Discussion. MTX/VBL remains a useful combination but PLD is emerging as a well tolerated and effective systemic therapy in advanced AF. © 2011 Informa Healthcare.en
dc.language.isoengen
dc.sourceActa Oncologicaen
dc.titleAdvanced aggressive fibromatosis: Effective palliation with chemotherapyen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3109/0284186X.2010.509105
dc.description.volume50
dc.description.issue3
dc.description.startingpage455
dc.description.endingpage461
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidConstantinidou, Anastasia [0000-0001-5316-7574]
dc.contributor.orcidJudson, Ian Robert [0000-0002-4766-5304]
dc.gnosis.orcid0000-0001-5316-7574
dc.gnosis.orcid0000-0002-4766-5304


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record